Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes-Reference-Cited by-同舟云学术

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes

Published:2022-01-11 Issue:2 Volume:327 Page:138
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Rubino Domenica M.¹,Greenway Frank L.²,Khalid Usman³,O’Neil Patrick M.⁴,Rosenstock Julio⁵,Sørrig Rasmus³,Wadden Thomas A.⁶,Wizert Alicja³,Garvey W. Timothy⁷,Arauz-Pacheco Carlos⁸,Cannon Kevin⁸,Downey H. Jackson⁸,Fitz-Patrick David⁸,Geohas Jeffrey⁸,Gerety Gregg⁸,Gilbert John⁸,Hollander Priscilla⁸,Klein Eric⁸,Laufer Karen⁸,O'Donnell Philip⁸,Rosenblit Paul⁸,Toth Phillip⁸,

Affiliation:

1. Washington Center for Weight Management and Research, Arlington, Virginia

2. Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge

3. Novo Nordisk A/S, Søborg, Denmark

4. Weight Management Center, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston

5. Dallas Diabetes Research Center at Medical City, Dallas, Texas

6. Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia

7. Department of Nutrition Sciences, University of Alabama at Birmingham

8. for the STEP 8 Investigators

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2787907/jama_rubino_2022_oi_210142_1641310203.77797.pdf

Reference36 articles.

1. Once-weekly semaglutide in adults with overweight or obesity.;Wilding;N Engl J Med,2021

2. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.;Davies;Lancet,2021

3. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial.;Wadden;JAMA,2021

4. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial.;Rubino;JAMA,2021

5. The discovery and development of liraglutide and semaglutide.;Knudsen;Front Endocrinol (Lausanne),2019

Cited by 438 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tratamiento farmacológico de la obesidad. Situación actual y nuevos tratamientos;Atención Primaria;2025-01

2. Antipsychotic Drugs;Massachusetts General Hospital Comprehensive Clinical Psychiatry;2025

3. Obstructive sleep apnea and obesity: A review of epidemiology, pathophysiology and the effect of weight-loss treatments;Sleep Medicine Reviews;2024-12

4. Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist;Gynecologic Oncology;2024-11

5. Exploring flavonoid intake and all-cause mortality in diverse health conditions: Insights from NHANES 2007–2010 and 2017–2018;Nutrition;2024-11